Literature DB >> 7002665

Diabetes is associated with autoimmunity in the New Zealand obese (NZO) mouse.

K A Melez, L C Harrison, J N Gilliam, A D Steinberg.   

Abstract

The New Zealand Obese (NZO) mouse was studied as a potential model for autoimmune diabetes. NZO mice develop obesity, glucose intolerance, and insulin resistance, and have low-titer IgM antibodies to the insulin receptor. It is shown that they have circulating antibodies to both native DNA and denatured, single-stranded DNA. The antibody levels are higher in females, and, up to 6 mo of age, are comparable to those found in the related NZB X NZW F1 (NZB/W) mouse, a model for systemic lupus erythematosus. After 6 mo of age the antibody levels in NZO mice fall toward normal, in contrast to the persistently elevated levels in NZB/W mice. NZB/W mice are known to succumb to immune complex-mediated proliferative glomerulonephritis before 1 yr of age, whereas NZO mice survive. NZO kidneys exhibit light microscopic features of both diabetic and lupus nephropathies: glomerular proliferation, mesangial deposits, mild basement membrane thickening, glomerulosclerosis, eosinophilic nodules in some glomeruli, occasional hyalinization of the glomerular arterioles, and healing arteriolar inflammation. These changes are associated with glomerular deposition of immunoglobulin, especially IgM, in a granular pattern on fluorescent staining. The NZO mouse, therefore, has evidence of a generalized immune disorder and provides a model for studying the relationship between autoimmunity, obesity, and diabetes.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7002665     DOI: 10.2337/diacare.20.10.835

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  10 in total

1.  Nonbinding inhibitory antiinsulin receptor antibodies. A new type of autoantibodies in human diabetes.

Authors:  G Boden; Y Fujita-Yamaguchi; R Shimoyama; J J Shelmet; L Tappy; I Rezvani; O E Owen
Journal:  J Clin Invest       Date:  1988-06       Impact factor: 14.808

2.  Autoantibodies to hormone receptors.

Authors:  L C Harrison
Journal:  Springer Semin Immunopathol       Date:  1982

Review 3.  Use of genetic mouse models in the study of diabetic nephropathy.

Authors:  Terri J Allen; Mark E Cooper; Hui Y Lan
Journal:  Curr Diab Rep       Date:  2004-12       Impact factor: 4.810

Review 4.  A review of rodent models of type 2 diabetic skeletal fragility.

Authors:  Roberto J Fajardo; Lamya Karim; Virginia I Calley; Mary L Bouxsein
Journal:  J Bone Miner Res       Date:  2014       Impact factor: 6.741

5.  Pancreatic cellular infiltrates in autoimmune-prone New Zealand Black mice.

Authors:  T A Seemayer; E Colle
Journal:  Diabetologia       Date:  1984-04       Impact factor: 10.122

Review 6.  Use of genetic mouse models in the study of diabetic nephropathy.

Authors:  Terri J Allen; Mark E Cooper; Hui Y Lan
Journal:  Curr Atheroscler Rep       Date:  2004-05       Impact factor: 5.113

Review 7.  New experimental models of diabetic nephropathy in mice models of type 2 diabetes: efforts to replicate human nephropathy.

Authors:  María José Soler; Marta Riera; Daniel Batlle
Journal:  Exp Diabetes Res       Date:  2012-02-08

8.  Metabolic and oxidative stress markers in Wistar rats after 2 months on a high-fat diet.

Authors:  Nathalie Auberval; Stéphanie Dal; William Bietiger; Michel Pinget; Nathalie Jeandidier; Elisa Maillard-Pedracini; Valérie Schini-Kerth; Séverine Sigrist
Journal:  Diabetol Metab Syndr       Date:  2014-11-28       Impact factor: 3.320

Review 9.  Animal Models of Diabetes-Associated Renal Injury.

Authors:  Zahra Samadi Noshahr; Hossein Salmani; Abolfazl Khajavi Rad; Amirhossein Sahebkar
Journal:  J Diabetes Res       Date:  2020-05-20       Impact factor: 4.011

Review 10.  Advances in murine models of diabetic nephropathy.

Authors:  Li-Li Kong; Hao Wu; Wen-Peng Cui; Wen-Hua Zhou; Ping Luo; Jing Sun; Hang Yuan; Li-Ning Miao
Journal:  J Diabetes Res       Date:  2013-06-13       Impact factor: 4.011

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.